|
1
|
Chaidemenos G, Apalla Z, Koussidou T,
Papagarifallou I and Ioannides D: High dose oral prednisone vs.
prednisone plus azathioprine for the treatment of oral pemphigus: A
retrospective, bi-centre, comparative study. J Eur Acad Dermatol
Venereol. 25:206–210. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Burgan SZ, Sawair FA and Napier SS: Case
report: Oral pemphigus vulgaris with multiple oral polyps in a
young patient. Int Dent J. 53:37–40. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lever WF and Talbott JH: Pemphigus: A
historical study. Arch Derm Syphilol. 46:800–823. 1942. View Article : Google Scholar
|
|
4
|
Alpsoy E, Akman-Karakas A and Uzun S:
Geographic variations in epidemiology of two autoimmune bullous
diseases: Pemphigus and bullous pemphigoid. Arch Dermatol Res.
307:291–298. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shah AA, Seiffert-Sinha K, Sirois D, Werth
VP, Rengarajan B, Zrnchik W, Attwood K and Sinha AA: Development of
a disease registry for autoimmune bullous diseases: Initial
analysis of the pemphigus vulgaris subset. Acta Derm Venereol.
95:86–90. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ramos-e-Silva M, Ferreira A and Jacques C:
Oral involvement in autoimmune bullous diseases. Clin Dermatol.
29:443–454. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stanley JR and Amagai M: Pemphigus,
bullous impetigo, and the staphylococcal scalded-skin syndrome. N
Engl J Med. 355:1800–1810. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Grando SA: Pemphigus autoimmunity:
Hypotheses and realities. Autoimmunity. 45:7–35. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Grando SA, Bystryn JC, Chernyavsky AI,
Frusić-Zlotkin M, Gniadecki R, Lotti R, Milner Y, Pittelkow MR and
Pincelli C: Apoptolysis: A novel mechanism of skin blistering in
pemphigus vulgaris linking the apoptotic pathways to basal cell
shrinkage and suprabasal acantholysis. Exp Dermatol. 18:764–770.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ahmed AR, Carrozzo M, Caux F, Cirillo N,
Dmochowski M, Alonso AE, Gniadecki R, Hertl M, López-Zabalza MJ,
Lotti R, et al: Monopathogenic vs multipathogenic explanations of
pemphigus pathophysiology. Exp Dermatol. 25:839–846. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Torzecka JD, Woźniak K, Kowalewski C,
Waszczykowska E, Sysa-Jedrzejowska A, Pas HH and Narbutt J:
Circulating pemphigus autoantibodies in healthy relatives of
pemphigus patients: Coincidental phenomenon with a risk of disease
development? Arch Dermatol Res. 299:239–243. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ruocco E, Wolf R, Ruocco V, Brunetti G,
Romano F and Lo Schiavo A: Pemphigus: associations and management
guidelines: facts and controversies. Clin Dermatol. 31:382–390.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vodo D, Sarig O and Sprecher E: The
genetics of pemphigus vulgaris. Front Med (Lausanne). 5:2262018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ruocco V, Ruocco E, Lo Schiavo A, Brunetti
G, Guerrera LP and Wolf R: Pemphigus: etiology, pathogenesis, and
inducing or triggering factors: facts and controversies. Clin
Dermatol. 31:374–381. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mao X, Sano Y, Park JM and Payne AS: p38
MAPK activation is downstream of the loss of intercellular adhesion
in pemphigus vulgaris. J Biol Chem. 286:1283–1291. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Saito M, Stahley SN, Caughman CY, Mao X,
Tucker DK, Payne AS, Amagai M and Kowalczyk AP: Signaling dependent
and independent mechanisms in pemphigus vulgaris blister formation.
PLoS One. 7:e506962012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yamagami J: Recent advances in the
understanding and treatment of pemphigus and pemphigoid. F1000Res.
(pii): F10002018.PubMed/NCBI
|
|
18
|
Witte M, Zillikens D and Schmidt E:
Diagnosis of autoimmune blistering diseases. Front Med (Lausanne).
5:2962018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shoimer I, Wong RX and Mydlarski PR:
Pemphigus VulgarisAutoimmune Bullous Diseases. Sami N: Springer
International Publishing; pp. 1–18. 2016, View Article : Google Scholar
|
|
20
|
Hammers CM, Chen J, Lin C, Kacir S, Siegel
DL, Payne AS and Stanley JR: Persistence of anti-desmoglein 3
IgG(+) B-cell clones in pemphigus patients over years. J Invest
Dermatol. 135:742–749. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xuan RR, Yang A and Murrell DF: New
biochip immunofluorescence test for the serological diagnosis of
pemphigus vulgaris and foliaceus: A review of the literature. Int J
Womens Dermatol. 4:102–108. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ilie MA, Caruntu C, Lupu M, Lixandru D,
Tampa M, Georgescu SR, Bastian A, Constantin C, Neagu M, Zurac SA,
et al: Current and future applications of confocal laser scanning
microscopy imaging in skin oncology. Oncol Lett. 17:4102–4111.
2019.PubMed/NCBI
|
|
23
|
Ilie MA, Caruntu C, Lixandru D, Tampa M,
Georgescu SR, Constantin MM, Constantin C, Neagu M, Zurac SA and
Boda D: In vivo confocal laser scanning microscopy imaging
of skin inflammation: Clinical applications and research
directions. Exp Ther Med. 17:1004–1011. 2019.PubMed/NCBI
|
|
24
|
Bystryn JC and Rudolph JL: Pemphigus.
Lancet. 366:61–73. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kridin K: Emerging treatment options for
the management of pemphigus vulgaris. Ther Clin Risk Manag.
14:757–778. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Harman KE, Brown D, Exton LS, Groves RW,
Hampton PJ, Mohd Mustapa MF, Setterfield JF and Yesudian PD:
British Association of Dermatologists' guidelines for the
management of pemphigus vulgaris. Br J Dermatol. 177:1170–1201.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Amagai M, Tanikawa A, Shimizu T, Hashimoto
T, Ikeda S, Kurosawa M, Niizeki H, Aoyama Y, Iwatsuki K and
Kitajima Y; Committee for Guidelines for the Management of
Pemphigus Disease, : Japanese guidelines for the management of
pemphigus. J Dermatol. 41:471–486. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hertl M, Jedlickova H, Karpati S,
Marinovic B, Uzun S, Yayli S, Mimouni D, Borradori L, Feliciani C,
Ioannides D, et al: Pemphigus. S2 Guideline for diagnosis and
treatment - guided by the European Dermatology Forum (EDF) in
cooperation with the European Academy of Dermatology and
Venereology (EADV). J Eur Acad Dermatol Venereol. 29:405–414. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Caplan A, Fett N, Rosenbach M, Werth VP
and Micheletti RG: Prevention and management of
glucocorticoid-induced side effects: A comprehensive review: A
review of glucocorticoid pharmacology and bone health. J Am Acad
Dermatol. 76:1–9. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Almugairen N, Hospital V, Bedane C,
Duvert-Lehembre S, Picard D, Tronquoy AF, Houivet E, D'incan M and
Joly P: Assessment of the rate of long-term complete remission off
therapy in patients with pemphigus treated with different regimens
including medium- and high-dose corticosteroids. J Am Acad
Dermatol. 69:583–588. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chams-Davatchi C, Mortazavizadeh A,
Daneshpazhooh M, Davatchi F, Balighi K, Esmaili N, Akhyani M,
Hallaji Z, Seirafi H and Mortazavi H: Randomized double blind trial
of prednisolone and azathioprine, vs. prednisolone and placebo, in
the treatment of pemphigus vulgaris. J Eur Acad Dermatol Venereol.
27:1285–1292. 2013.PubMed/NCBI
|
|
32
|
Beissert S, Mimouni D, Kanwar AJ, Solomons
N, Kalia V and Anhalt GJ: Treating pemphigus vulgaris with
prednisone and mycophenolate mofetil: A multicenter, randomized,
placebo-controlled trial. J Invest Dermatol. 130:2041–2048. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Porro AM, Hans Filho G and Santi GH:
Consensus on the treatment of autoimmune bullous dermatoses:
Pemphigus vulgaris and pemphigus foliaceus - Brazilian Society of
Dermatology. An Bras Dermatol. 94 (Suppl 1):20–32. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Baum S, Greenberger S, Samuelov L, Solomon
M, Lyakhovitsky A, Trau H and Barzilai A: Methotrexate is an
effective and safe adjuvant therapy for pemphigus vulgaris. Eur J
Dermatol. 22:83–87. 2012.PubMed/NCBI
|
|
35
|
Olszewska M, Kolacinska-Strasz Z, Sulej J,
Labecka H, Cwikla J, Natorska U and Blaszczyk M: Efficacy and
safety of cyclophosphamide, azathioprine, and cyclosporine
(ciclosporin) as adjuvant drugs in pemphigus vulgaris. Am J Clin
Dermatol. 8:85–92. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Joly P, Maho-Vaillant M, Prost-Squarcioni
C, Hebert V, Houivet E, Calbo S, Caillot F, Golinski ML, Labeille
B, Picard-Dahan C, et al French study group on autoimmune bullous
skin diseases, : First-line rituximab combined with short-term
prednisone versus prednisone alone for the treatment of pemphigus
(Ritux 3): A prospective, multicentre, parallel-group, open-label
randomised trial. Lancet. 389:2031–2040. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Amagai M, Ikeda S, Shimizu H, Iizuka H,
Hanada K, Aiba S, Kaneko F, Izaki S, Tamaki K, Ikezawa Z, et al
Pemphigus Study Group, : A randomized double-blind trial of
intravenous immunoglobulin for pemphigus. J Am Acad Dermatol.
60:595–603. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tavakolpour S, Mirsafaei HS and Delshad S:
Management of pemphigus disease in pregnancy. Am J Reprod Immunol.
77:e126012017. View Article : Google Scholar
|
|
39
|
Guillaume JC, Roujeau JC, Morel P, Doutre
MS, Guillot B, Lambert D, Lauret P, Lorette G, Prigent F, Triller
R, et al: Controlled study of plasma exchange in pemphigus. Arch
Dermatol. 124:1659–1663. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kolesnik M, Becker E, Reinhold D, Ambach
A, Heim MU, Gollnick H and Bonnekoh B: Treatment of severe
autoimmune blistering skin diseases with combination of protein A
immunoadsorption and rituximab: A protocol without initial high
dose or pulse steroid medication. J Eur Acad Dermatol Venereol.
28:771–780. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kasperkiewicz M, Shimanovich I, Meier M,
Schumacher N, Westermann L, Kramer J, Zillikens D and Schmidt E:
Treatment of severe pemphigus with a combination of
immunoadsorption, rituximab, pulsed dexamethasone and
azathioprine/mycophenolate mofetil: A pilot study of 23 patients.
Br J Dermatol. 166:154–160. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ellebrecht CT, Choi EJ, Allman DM, Tsai
DE, Wegener WA, Goldenberg DM and Payne AS: Subcutaneous
veltuzumab, a humanized anti-CD20 antibody, in the treatment of
refractory pemphigus vulgaris. JAMA Dermatol. 150:1331–1335. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ellebrecht CT, Bhoj VG, Nace A, Choi EJ,
Mao X, Cho MJ, Di Zenzo G, Lanzavecchia A, Seykora JT, Cotsarelis
G, et al: Reengineering chimeric antigen receptor T cells for
targeted therapy of autoimmune disease. Science. 353:179–184. 2016.
View Article : Google Scholar : PubMed/NCBI
|
